- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.08. | TriSalus Life Sciences GAAP EPS of -$0.16 misses by $0.01, revenue of $11.41M beats by $1.14M | 2 | Seeking Alpha | ||
| 07.08. | Trisalus reiterates 2026 revenue guidance of $54M-$57M as CMS G-code expands TriNav reimbursement into office-based labs | 1 | Seeking Alpha | ||
| 06.08. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | TriSalus Life Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.06. | Canaccord reiterates TriSalus stock Buy rating after KOL event | 1 | Investing.com | ||
| 18.05. | TriSalus Life Sciences: Aktie steigt trotz Umsatzrückgang im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 13.05. | TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal | 1 | Seeking Alpha | ||
| 12.05. | TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 12.05. | TriSalus Life Sciences GAAP EPS of $0.03 beats by $0.19, revenue of $8.9M misses by $1.54M | 2 | Seeking Alpha | ||
| 12.05. | TriSalus senkt Umsatzprognose für 2026 auf 54-57 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 12.05. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.05. | TriSalus startet PREDICTT-Studie zur Behandlung von Lebertumoren | 1 | Investing.com Deutsch | ||
| 04.05. | TriSalus initiates PREDICTT trial for liver tumor treatment | 1 | Investing.com | ||
| 09.04. | TriSalus to present drug delivery data at radiology meeting | 1 | Investing.com | ||
| 07.04. | TriSalus ernennt Richard Marshall zum Chief Medical Officer | 2 | Investing.com Deutsch | ||
| 07.04. | TriSalus names Richard Marshall as chief medical officer | 2 | Investing.com | ||
| 07.04. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 14,950 | -1,09 % | Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? | ||
| SYNBIOTIC | 0,851 | -6,28 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 9,578 | +1,35 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,080 | 0,00 % | Oramed Pharmaceuticals: Aktionäre bestätigen Verwaltungsrat und billigen Anpassung des Aktienplans | ||
| SELLAS LIFE SCIENCES | 9,720 | -2,80 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| OPKO HEALTH | 1,390 | -4,79 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,777 | +8,86 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| OPUS GENETICS | 4,480 | -0,44 % | Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? | ||
| SOLIGENIX | 0,370 | -3,77 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results |
PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| TALPHERA | 1,010 | -0,98 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,631 | +0,32 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| SCYNEXIS | 3,810 | -1,93 % | Scynexis appoints Todd Minga as senior VP of R&D | ||
| PROTHENA | 7,600 | +1,93 % | Prothena Corporation plc: Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,860 | +2,12 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Completion of Redomiciliation to Delaware | CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,790 | +0,56 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers | TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel... ► Artikel lesen |
Das Unternehmen TRISALUS LIFE SCIENCES INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,030 (-0,59 %) liegt der Kurs bei 5,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.